moleculomics limited
moleculomics limited Company Information
Company Number
08340228
Next Accounts
Mar 2025
Directors
Shareholders
jonathan gregory lloyd mullins
swansea innovations ltd
View AllGroup Structure
View All
Industry
Other research and experimental development on natural sciences and engineering
Registered Address
48 mumbles road, blackpill, swansea, SA3 5AU
Website
moleculomics.commoleculomics limited Estimated Valuation
Pomanda estimates the enterprise value of MOLECULOMICS LIMITED at £26.3k based on a Turnover of £30.1k and 0.87x industry multiple (adjusted for size and gross margin).
moleculomics limited Estimated Valuation
Pomanda estimates the enterprise value of MOLECULOMICS LIMITED at £0 based on an EBITDA of £-19.9k and a 4.13x industry multiple (adjusted for size and gross margin).
moleculomics limited Estimated Valuation
Pomanda estimates the enterprise value of MOLECULOMICS LIMITED at £0 based on Net Assets of £-22.1k and 1.93x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Moleculomics Limited Overview
Moleculomics Limited is a dissolved company that was located in swansea, SA3 5AU with a Companies House number of 08340228. It operated in the other research and experimental development on natural sciences and engineering sector, SIC Code 72190. Founded in December 2012, it's largest shareholder was jonathan gregory lloyd mullins with a 65% stake. The last turnover for Moleculomics Limited was estimated at £30.1k.
Upgrade for unlimited company reports & a free credit check
Moleculomics Limited Health Check
Pomanda's financial health check has awarded Moleculomics Limited a 1 rating. We use a traffic light system to show it exceeds the industry average on 1 measures and has 6 areas for improvement. Company Health Check FAQs
1 Strong
1 Regular
6 Weak
Size
annual sales of £30.1k, make it smaller than the average company (£3.7m)
- Moleculomics Limited
£3.7m - Industry AVG
Growth
3 year (CAGR) sales growth of -39%, show it is growing at a slower rate (5%)
- Moleculomics Limited
5% - Industry AVG
Production
with a gross margin of 26.2%, this company has a higher cost of product (48.1%)
- Moleculomics Limited
48.1% - Industry AVG
Profitability
an operating margin of -65.9% make it less profitable than the average company (4.4%)
- Moleculomics Limited
4.4% - Industry AVG
Employees
with 1 employees, this is below the industry average (44)
- Moleculomics Limited
44 - Industry AVG
Pay Structure
on an average salary of £62.3k, the company has an equivalent pay structure (£62.3k)
- Moleculomics Limited
£62.3k - Industry AVG
Efficiency
resulting in sales per employee of £30.1k, this is less efficient (£115.5k)
- Moleculomics Limited
£115.5k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- Moleculomics Limited
- - Industry AVG
Creditor Days
its suppliers are paid after 363 days, this is slower than average (44 days)
- Moleculomics Limited
44 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Moleculomics Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Moleculomics Limited
- - Industry AVG
Debt Level
There is insufficient data available for this Key Performance Indicator!
- - Moleculomics Limited
- - Industry AVG
MOLECULOMICS LIMITED financials
Moleculomics Limited's latest turnover from July 2023 is estimated at £30.1 thousand and the company has net assets of -£22.1 thousand. According to their latest financial statements, we estimate that Moleculomics Limited has 1 employee and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Jul 2023 | Jul 2022 | Jul 2021 | Jul 2020 | Jul 2019 | Jul 2018 | Jul 2017 | Jul 2016 | Jul 2015 | Jul 2014 | Jul 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | |||||||||||
| Other Income Or Grants | |||||||||||
| Cost Of Sales | |||||||||||
| Gross Profit | |||||||||||
| Admin Expenses | |||||||||||
| Operating Profit | |||||||||||
| Interest Payable | |||||||||||
| Interest Receivable | |||||||||||
| Pre-Tax Profit | |||||||||||
| Tax | |||||||||||
| Profit After Tax | |||||||||||
| Dividends Paid | |||||||||||
| Retained Profit | |||||||||||
| Employee Costs | |||||||||||
| Number Of Employees | 1 | 1 | 5 | ||||||||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Jul 2023 | Jul 2022 | Jul 2021 | Jul 2020 | Jul 2019 | Jul 2018 | Jul 2017 | Jul 2016 | Jul 2015 | Jul 2014 | Jul 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | |||||||||||
| Intangible Assets | |||||||||||
| Investments & Other | |||||||||||
| Debtors (Due After 1 year) | |||||||||||
| Total Fixed Assets | |||||||||||
| Stock & work in progress | |||||||||||
| Trade Debtors | 17,310 | 42,975 | 57,264 | 39,444 | 37,342 | 14,500 | 17,000 | 15,749 | 33,094 | ||
| Group Debtors | |||||||||||
| Misc Debtors | |||||||||||
| Cash | 59,373 | 136,847 | 122,528 | 20,425 | |||||||
| misc current assets | |||||||||||
| total current assets | 17,310 | 42,975 | 57,264 | 39,444 | 37,342 | 73,873 | 153,847 | 138,277 | 53,519 | ||
| total assets | 17,310 | 42,975 | 57,264 | 39,444 | 37,342 | 73,873 | 153,847 | 138,277 | 53,519 | ||
| Bank overdraft | |||||||||||
| Bank loan | |||||||||||
| Trade Creditors | 22,135 | 19,566 | 30,260 | 38,865 | 16,221 | 17,390 | 19,382 | 11,800 | 30,593 | 24,157 | |
| Group/Directors Accounts | |||||||||||
| other short term finances | |||||||||||
| hp & lease commitments | |||||||||||
| other current liabilities | |||||||||||
| total current liabilities | 22,135 | 19,566 | 30,260 | 38,865 | 16,221 | 17,390 | 19,382 | 11,800 | 30,593 | 24,157 | |
| loans | |||||||||||
| hp & lease commitments | |||||||||||
| Accruals and Deferred Income | |||||||||||
| other liabilities | |||||||||||
| provisions | |||||||||||
| total long term liabilities | |||||||||||
| total liabilities | 22,135 | 19,566 | 30,260 | 38,865 | 16,221 | 17,390 | 19,382 | 11,800 | 30,593 | 24,157 | |
| net assets | -22,135 | -2,256 | 12,715 | 18,399 | 23,223 | 19,952 | 54,491 | 142,047 | 107,684 | 29,362 | |
| total shareholders funds | -22,135 | -2,256 | 12,715 | 18,399 | 23,223 | 19,952 | 54,491 | 142,047 | 107,684 | 29,362 |
| Jul 2023 | Jul 2022 | Jul 2021 | Jul 2020 | Jul 2019 | Jul 2018 | Jul 2017 | Jul 2016 | Jul 2015 | Jul 2014 | Jul 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||
| Operating Profit | |||||||||||
| Depreciation | |||||||||||
| Amortisation | |||||||||||
| Tax | |||||||||||
| Stock | |||||||||||
| Debtors | -17,310 | -25,665 | -14,289 | 17,820 | 2,102 | 22,842 | -2,500 | 1,251 | -17,345 | 33,094 | |
| Creditors | 2,569 | -10,694 | -8,605 | 22,644 | -1,169 | -1,992 | 7,582 | -18,793 | 6,436 | 24,157 | |
| Accruals and Deferred Income | |||||||||||
| Deferred Taxes & Provisions | |||||||||||
| Cash flow from operations | |||||||||||
| Investing Activities | |||||||||||
| capital expenditure | |||||||||||
| Change in Investments | |||||||||||
| cash flow from investments | |||||||||||
| Financing Activities | |||||||||||
| Bank loans | |||||||||||
| Group/Directors Accounts | |||||||||||
| Other Short Term Loans | |||||||||||
| Long term loans | |||||||||||
| Hire Purchase and Lease Commitments | |||||||||||
| other long term liabilities | |||||||||||
| share issue | |||||||||||
| interest | |||||||||||
| cash flow from financing | |||||||||||
| cash and cash equivalents | |||||||||||
| cash | -59,373 | -77,474 | 14,319 | 102,103 | 20,425 | ||||||
| overdraft | |||||||||||
| change in cash | -59,373 | -77,474 | 14,319 | 102,103 | 20,425 |
moleculomics limited Credit Report and Business Information
Moleculomics Limited Competitor Analysis
Perform a competitor analysis for moleculomics limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other undefined companies, companies in SA3 area or any other competitors across 12 key performance metrics.
moleculomics limited Ownership
MOLECULOMICS LIMITED group structure
Moleculomics Limited has no subsidiary companies.
Ultimate parent company
MOLECULOMICS LIMITED
08340228
moleculomics limited directors
Moleculomics Limited currently has 1 director, Dr Jonathan Mullins serving since Dec 2012.
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Dr Jonathan Mullins | Wales | 57 years | Dec 2012 | - | Director |
P&L
July 2023turnover
30.1k
-51%
operating profit
-19.9k
0%
gross margin
26.3%
+9.12%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
July 2023net assets
-22.1k
+8.81%
total assets
0
-1%
cash
0
0%
net assets
Total assets minus all liabilities
Similar Companies
moleculomics limited company details
company number
08340228
Type
Private limited with Share Capital
industry
72190 - Other research and experimental development on natural sciences and engineering
incorporation date
December 2012
age
13
incorporated
UK
ultimate parent company
accounts
Micro-Entity Accounts
last accounts submitted
July 2023
previous names
N/A
accountant
-
auditor
-
address
48 mumbles road, blackpill, swansea, SA3 5AU
Bank
-
Legal Advisor
-
moleculomics limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to moleculomics limited.
moleculomics limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for MOLECULOMICS LIMITED. This can take several minutes, an email will notify you when this has completed.
moleculomics limited Companies House Filings - See Documents
| date | description | view/download |
|---|
